PRINCETON, N.J.– UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise treatment approach to low-grade Upper Tract Urothelial Cancer (LG UTUC) from initial ureteroscopy to nephrostomy placement, Jelmyto administration, and eventual nephrostomy removal.
“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” says Katie Murray, DO, Division of Urology, Department of Surgery, University of Missouri School of Medicine, Columbia, MO. “This report showed that antegrade instillation provided a well-tolerated and effective method of Jelmyto administration. In our experience we did not see a negative impact on patient comfort. Of note, our experience with antegrade administration in this analysis suggests that this approach, which minimizes manipulation of the ureter during instillation, may help protect against stricture formation which has been associated with repetitive instrumentation of the upper urinary tract. Given the potential benefits of antegrade versus retrograde administration of Jelmyto, we now have a replicable protocol to follow for antegrade administration using a nephrostomy tube.”
In both retrograde and antegrade approaches, Jelmyto can be administered as an outpatient procedure in the clinic. Retrograde administration requires administration by a physician via a ureteral catheter, requiring fluoroscopic guidance. Antegrade administration may be performed by trained nursing professionals under clean rather than sterile conditions and does not require fluoroscopy after a nephrostogram confirms placement at the first instillation.
“Choosing the optimal treatment modality for administration of Jelmyto is very important and can have significant implications for successful treatment and recovery,” said Mark Schoenberg, MD, Chief Medical Officer, UroGen. “Dr. Murray and her colleagues offer practical guidance for antegrade administration of Jelmyto, which can help reduce some of the complexity stakeholders may experience using retrograde administration.”
